Prostate Specific Membrane Antigen Targeted Positron Emission Tomography of Primary Prostate Cancer: Assessing Accuracy with Whole Mount Pathology

被引:15
|
作者
Bahler, Clinton D. [1 ]
Green, Mark [2 ]
Hutchins, Gary D. [2 ]
Cheng, Liang [3 ]
Magers, Martin J. [3 ]
Fletcher, James [2 ]
Koch, Michael O. [1 ]
机构
[1] Indiana Univ, Dept Urol, Indianapolis, IN 46204 USA
[2] Indiana Univ, Dept Radiol, Indianapolis, IN 46204 USA
[3] Indiana Univ, Dept Pathol, Indianapolis, IN 46204 USA
基金
美国国家卫生研究院;
关键词
prostatic neoplasms; positron-emission tomography; pathology; surgical; risk; early detection of cancer; RADICAL PROSTATECTOMY; GLEASON PATTERN-4; TUMOR VOLUME; MEN; PROGRESSION; BIOPSY; PERCENTAGE; PREDICTOR; PET/CT;
D O I
10.1097/JU.0000000000000501
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: We evaluated which lesions are detected and missed on [Ga-68]Ga-PSMA (prostate specific membrane antigen)-11 positron emission tomography in patients with primary prostate cancer. Materials and Methods: Patients undergoing radical prostatectomy were enrolled in this prospective observational study. Patients underwent [Ga-68] Ga-PSMA-11 positron emission tomography/computerized tomography or positron emission tomography/magnetic resonance imaging prior to surgery and received a dose of [Ga-68] Ga-PSMA-11 intraoperatively for positron emission tomography of extirpated specimens. Whole mount pathology was performed with lesion and intralesion based analysis to determine the characteristics of lesions detected or not detected by PSMA positron emission tomography. Lesion volume was determined by planimetry and clinically significant lesion volume was calculated as lesion volume x fraction pattern 4/5. Results: On whole mount analysis 30 cancerous lesions were found in a total of 15 patients, including 4, 15, 4, 1 and 6 which were Grade Group 1, 2, 3, 4 and 5, respectively. PSMA-positron emission tomography detected 100% of primary/index lesions and 8 of 11 (82%) secondary lesions. All Grade Group 3-5 lesions were detected vs 12 of 15 Grade Group 2 lesions. When comparing Grade Group 2 vs 3-5, lesion size was similar (p = 0.48) but the standardized uptake value was lower for Grade Group 2 vs 3-5 (5.3 vs 7.9, p = 0.03). The 3 missed lesions showed 10% or less of pattern 4 and a Gleason pattern 4/5 volume of less than 0.1 cm(3). Conclusions: PSMA positron emission tomography detected 100% of primary/index lesions in this study. The 3 missed secondary lesions were small and had a low percent of pattern 4. This argues for further study to better understand what defines clinically significant prostate cancer, which would assist in determining whether small lesions that become challenging to detect by [Ga-68]Ga-PSMA-11 positron emission tomography confer a risk to the patient.
引用
收藏
页码:92 / 99
页数:8
相关论文
共 50 条
  • [41] Comparison of 68Ga-labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Magnetic Resonance Imaging and Positron Emission Tomography/Computed Tomography for Primary Staging of Prostate Cancer: A Systematic Review and Meta-analysis
    Ling, Sui Wai
    de Jong, Anouk C.
    Schoots, Ivo G.
    Nasserinejad, Kazem
    Busstra, Martijn B.
    van der Veldt, Astrid A. M.
    Brabander, Tessa
    EUROPEAN UROLOGY OPEN SCIENCE, 2021, 33 : 61 - 71
  • [42] Dose-Escalated Salvage Radiotherapy for Macroscopic Local Recurrence of Prostate Cancer in the Prostate-Specific Membrane Antigen Positron Emission Tomography Era
    Tamihardja, Jorg
    Zehner, Leonie
    Hartrampf, Philipp E.
    Cirsi, Sinan
    Wegener, Sonja
    Buck, Andreas K.
    Flentje, Michael
    Polat, Bulent
    CANCERS, 2022, 14 (19)
  • [43] The Role of Radiolabeled Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography for the Evaluation of Renal Cancer
    Evangelista, Laura
    Basso, Umberto
    Maruzzo, Marco
    Novara, Giacomo
    EUROPEAN UROLOGY FOCUS, 2020, 6 (01): : 146 - 150
  • [44] Multicenter External Validation of a Nomogram for Predicting Positive Prostate-specific Membrane Antigen/Positron Emission Tomography Scan in Patients with Prostate Cancer Recurrence
    Bianchi, Lorenzo
    Castellucci, Paolo
    Farolfi, Andrea
    Droghetti, Matteo
    Artigas, Carlos
    Leite, Jose
    Corona, Paola
    Shagera, Qaid Ahmed
    Moreira, Renata
    Gonzalez, Christian
    Queiroz, Marcelo
    Barbosa, Felipe de Galiza
    Schiavina, Riccardo
    Deandreis, Desiree
    Fanti, Stefano
    Ceci, Francesco
    EUROPEAN UROLOGY ONCOLOGY, 2023, 6 (01): : 41 - 48
  • [45] Cost-Effectiveness Analysis of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography/Computed Tomography (PET/CT) for the Primary Staging of Prostate Cancer in Australia
    Song, Rachel
    Jeet, Varinder
    Sharma, Rajan
    Hoyle, Martin
    Parkinson, Bonny
    PHARMACOECONOMICS, 2022, 40 (08) : 807 - 821
  • [46] Prostate-specific membrane antigen-positron emission tomography (PSMA-PET) of prostate cancer: current and emerging applications
    Shamus Moran
    Heather H. Cheng
    Emily Weg
    Eric H. Kim
    Delphine L. Chen
    Amir Iravani
    Joseph E. Ippolito
    Abdominal Radiology, 2024, 49 : 1288 - 1305
  • [47] Targeted Therapies for Prostate Cancer Against the Prostate Specific Membrane Antigen
    Elsaesser-Beile, U.
    Buehler, P.
    Wolf, P.
    CURRENT DRUG TARGETS, 2009, 10 (02) : 118 - 125
  • [48] Prostate-specific membrane antigen-positron emission tomography (PSMA-PET) of prostate cancer: current and emerging applications
    Moran, Shamus
    Cheng, Heather H.
    Weg, Emily
    Kim, Eric H.
    Chen, Delphine L.
    Iravani, Amir
    Ippolito, Joseph E.
    ABDOMINAL RADIOLOGY, 2024, 49 (04) : 1288 - 1305
  • [49] Vas deferens infiltration by prostate cancer on prostate-specific membrane antigen-targeted18F-DCFPyL positron emission tomography/computed tomography: A unique visual pattern
    Yin, Yafu
    Paller, Channing J.
    Pomper, Martin G.
    Pienta, Kenneth J.
    Gorin, Michael A.
    Rowe, Steven P.
    WORLD JOURNAL OF NUCLEAR MEDICINE, 2019, 18 (04) : 424 - 427
  • [50] Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Active Surveillance for Prostate Cancer Trial (PASPoRT)
    Heetman, Joris G.
    Lavalaye, Jules
    Polm, Pepijn D.
    Soeterik, Timo F. W.
    Wever, Lieke
    Pereira, Leonor J. Paulino
    van der Hoeven, Erik J. R. J.
    van Melick, Harm H. E.
    van den Bergh, Roderick C. N.
    EUROPEAN UROLOGY ONCOLOGY, 2024, 7 (02): : 204 - 210